Answers are grounded in this paper and cite their sources.
If diversity is defined as the inclusion of a range of many people that are different from each other, then it is obviously a core principle guiding best practices in clinical pharmacology and the foundation for personalized medicine and precision dosing.1 The editorial team of Clinical Pharmacology & Therapeutics (CPT) is proud to present a series of articles in this special issue of the journal (Figure 1) that highlight the critical, and at times ground-breaking, role leaders in our discipline are playing to push the scientific and cultural boundaries of clinical pharmacology in the context of diversity, specifically with regard to gender/biological sex, ethnicity/race, age, and specific populations, such as pregnant people and their unborn children (Figure 2). In a timely and landmark state-of-the-art review, Cirrincione and Huang2 provide an in-depth assessment of sex- and gender-related differences in clinical pharmacology and their implications for transgender medicine. Despite the fact that 25 million people aged 15 years and older worldwide are transgender and that this population is growing, transgender medicine is still an evolving and relatively young discipline and there is a lack of clinical pharmacology data in transgender individuals. In the accompanying Commentary, Cotreau3 points out that at the moment there are far more questions than answers in this area and suggests that a new clinical pharmacology subspeciality may need to emerge to better serve this growing population. We agree that organizations, such as the American Society for Clinical Pharmacology & Therapeutics (ASCPT) and their journals should take the lead in this. The second state-of-the-art review in this month’s issue from Davis and Limdi4 discusses the important topic of the role of translational pharmacogenomics as it pertains to race-conscious medicine and how the discovery of race-ancestry-specific pharmacogenetic variants that impact drug response has demonstrated the potential to develop and implement new actionable clinical pharmacology frameworks. Like transgender medicine, race-conscious medicine (and clinical pharmacology’s contributions to them) is still in its infancy and as a society and discipline we have to commit to “a sustained (often-uncomfortable) dialogue” as a first step toward delivering better treatments for every individual.4 For example, Ikediobi5 argues that “ethnicity is not a proxy for genetics” and that ethnicity-driven pharmacogenomic biomarker testing has significant limitations and has resulted in a fundamental gap in the clinical implementation of pharmacogenomic information for allopurinol leading to health disparity. Age is the third dimension of diversity covered in the current issue (Figure 2). In their White Paper, Rei Bolislis and co-workers from 11 pharmaceutical companies describe the bottlenecks and challenges identified by industry with the implementation of the European Union’s Pediatric Regulation and propose solutions to further support the implementation of the European Medicines Agency (EMA)-European Commission (EC) Joint Action Plan on Paediatrics.6 Along the same lines, Beck et al. present a study of the regulatory challenges of pediatric oncology trial submissions and provide a guideline describing the key regulatory aspects in this area.7 A study from the US Food and Drug Administration (FDA) found that despite the success of the 1983 Orphan Drug Act (ODA), orphan drug labeling for pediatric patients under 2 years of age is still far from complete and they propose that new strategies need to be explored to include infants and neonates.8 An example of such a strategy is the Benefit and Risk Assessment for Off-label use (BRAvO) framework, described in the Tutorial by van der Zanden and colleagues9 as a tool to guide age-appropriate dose selection in children. The development and implementation of individualized treatment regimens for pediatric patients in developing countries is often made even more challenging due to additional complicating factors, such as malnutrition and comedication.10 Hughes et al. illustrate how pharmacokinetic-pharmacodynamic (PKPD) modeling has been used to optimize malaria treatment regimens in this and other vulnerable patient populations and suggest other disease areas could achieve similar success by implementing the lessons learned.11 At the other end of the age spectrum are the elderly, who have been described as “a neglected and growing population” in this journal.12 The need for more patient-centric clinical pharmacology for older persons was emphasized in the recent FDA workshop “Roadmap to 2030 for New Drug Evaluation in Older Adults”13 and Hsu et al. present an example of such an approach in the current issue for anticholinergic therapies.14 In addition to gender/sex, ethnicity/race and age, there are many other special populations that comprise the fourth dimension of diversity illustrated in this issue. One example is pregnant and breastfeeding people and their children (Figure 2). In a joint review from representatives from the UK, EU, and US regulatory agencies,15 solutions are proposed to improve knowledge on drug safety during pregnancy and breastfeeding, which should reduce current barriers for access to effective medicines in this special population.11, 16, 17 For example, opioid use in breastfeeding mothers has increased significantly over the past couple of decades and remains a controversial topic that continues to attract a lot of attention in the scientific literature and media.18 In the current issue, Zipursky and co-workers from Ontario build on their previous work in this area19 and present an analysis of trends in postpartum opioid prescriptions from 2000–2017 and conclude that a decline in overall opioid prescription as well as a shift to stronger opioids occurred following publication of a case report in 2006, which attributed the death of a breastfeeding neonate to maternal codeine use.20 In our April themed issue on Therapeutic Innovations in Infectious Diseases, we published the first series of “Special Populations” reviews associated with a specific therapeutic area21-24 and we are planning to continue this in the upcoming themed issue on Therapeutic Innovations in Neuroscience, scheduled for publication in April 2022. Of course, the realization that diverse patient populations should be included in clinical trials is not new, however, implementation has been slow and patchy. A potential positive, longer-term outcome from the coronavirus disease 2019 (COVID-19) pandemic may be that it has shown that, if needed, we can rapidly change entrenched paradigms in drug development. Shifts in the socio-economic and demographic landscape24 and expectations from patients and society25 will further catalyze the diversity and inclusion agenda in clinical pharmacology. In addition, a range of new translational and quantitative tools are now available to underpin new inclusive clinical development strategies.26 For example, a recent study published in this journal showed how a combination of mechanistic quantitative systems pharmacology modeling and machine learning provided new insights into sex-specific classification of drug-induced Torsade de Pointes (TdP) susceptibility.27 Notably, it was demonstrated that male-biased predictive models consistently underestimate TdP risk in women, which suggests that current standard preclinical and clinical safety assessment paradigms are inadequate. The evidence that women are also under-represented in author, reviewer, and editorial positions across scientific and medical journals has been well-documented28, 29 and there is no reason to believe CPT is an outlier in this respect, as demonstrated in our second editorial in this month’s issue.30 There is clearly a lot of critical and urgent work to be done, and the editorial team of CPT and its owner ASCPT will continue to “turn statements of commitment into action” and welcome your support, criticism and guidance.30 The much needed meaningful and timely progress in this area requires better and continuous collection, monitoring and assessment of data, and interaction with the journal’s main stakeholder groups (Figure 2). No funding was received for this work. The author declared no competing interests for this work.
No takes yet. Share an insight, caveat, or question.
Piet H. van der Graaf (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: